Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    OA03 - Molecular Targeted Treatments

    • 14:30 - 15:40
    • 8/07/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C

      14:52 - 15:02  |  Presenter: Michael Thomas

      • Abstract

      Loading...

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-028 - Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer

      Presenter: Emily Pei-Ying Lin

      • Abstract

      Loading...

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-029 - Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

      Presenter: James Chih-Hsin Yang

      • Abstract

      Loading...

    • +

      EP08.02-127 - Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

      Presenter: Bin-Chi Liao

      • Abstract

      Loading...

    • +

      EP08.02-140 - MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

      Presenter: Myung-Ju Ahn

      • Abstract

      Loading...

  • +

    OA12 - Novel and Combination Strategies for SCLC

    • 16:00 - 17:00
    • 8/08/2022
    • Location: Hall C8
    • Not for CME Credit
    • Type: Oral
    • Track: Small Cell Lung Cancer and Neuro-Endocrine Tumors
    • +

      OA12.06 - First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

      16:32 - 16:42  |  Presenter: Charles M Rudin

      • Abstract

      Loading...

  • +

    OA15 - Patient Selection in Advanced NSCLC Immunotherapy

    • 14:30 - 15:30
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      OA15.03 - Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100

      14:32 - 14:42  |  Presenter: Martin Reck

      • Abstract

      Loading...